This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n23http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00578/identifier/chebi/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00578/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00578/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00578/identifier/kegg-compound/
n24http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB00578/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00578/identifier/pubchem-substance/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00578/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n25http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00578/identifier/chemspider/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00578
rdf:type
n3:Drug
n3:description
Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function. [PubChem]
n3:group
approved
n3:halfLife
1 hour
n3:indication
For the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria.
n3:manufacturer
n5:271B4D6E-363D-11E5-9242-09173F13E4C5 n5:271B4D6D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00578 n24:DB00578
dcterms:title
Carbenicillin
adms:identifier
n10:PA448788 n11:20824 n12:DB00578 n17:C06869 n18:3393 n19:19599 n20:Carbenicillin n21:46505653
n3:mechanismOfAction
Free carbenicillin is the predominant pharmacologically active fraction of the salt. Carbenicillin exerts its antibacterial activity by interference with final cell wall synthesis of susceptible bacteria. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that carbenicillin interferes with an autolysin inhibitor.
n3:packager
n5:271B4D6C-363D-11E5-9242-09173F13E4C5 n5:271B4D6B-363D-11E5-9242-09173F13E4C5
n3:synonym
(2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid Carbenicilina alpha-Phenyl(carboxymethylpenicillin) Carbenicillin Carbenicilline CBPC alpha-Carboxybenzylpencillin Carbenicillinum Carboxybenzylpenicillin
n3:toxicity
Carbenicillin blood levels achievable are very low, and toxic reactions as a function of overdosage should not occur systematically. The oral LD<sub>50</sub> in mice is 3,600 mg/kg, in rats 2,000 mg/kg, and in dogs is in excess of 500 mg/kg. The lethal human dose is not known. Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.
n3:foodInteraction
Take on an empty stomach.
n3:proteinBinding
30 to 60%
n3:synthesisReference
Brain, E.G. and Nayler, J.H.C.; US. Patents 3,282,926; November 1,1966 and 3,492,291; January 27,1970; both assigned to Beecham Group Limited, England.
n7:hasConcept
n8:M0003339
foaf:page
n23:geocillin.htm n25:carbenicillin-indanyl.html
n3:IUPAC-Name
n4:271B4D73-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4D79-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4D78-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4D75-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4D76-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4D77-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4D89-363D-11E5-9242-09173F13E4C5 n4:271B4D71-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4D8A-363D-11E5-9242-09173F13E4C5 n4:271B4D6F-363D-11E5-9242-09173F13E4C5 n4:271B4D72-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4D70-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:J01CA03
n3:H-Bond-Acceptor-Count
n4:271B4D7F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4D80-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4D7A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4D7B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4D7D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4D7C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4D7E-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed from the small intestine following oral administration. Oral bioavailability is 30 to 40%.
n3:affectedOrganism
Proteus mirabilis Enteric bacteria and other eubacteria Gram-negative Bacteria Escherichia coli Pseudomonas aeruginosa
n3:casRegistryNumber
4697-36-3
n3:category
n3:Bioavailability
n4:271B4D85-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4D87-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4D88-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4D84-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4D83-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4D86-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4D74-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4D81-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4D82-363D-11E5-9242-09173F13E4C5